HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLOUDBREAK-B

2.260

+0.0100.44%

Volume:95.00K

Turnover:214.83K

Market Cap:1.92B

PE:-10.84

High:2.280

Open:2.250

Low:2.240

Close:2.250

52wk High:9.740

52wk Low:2.110

Shares:850.00M

HK Float Shares:850.00M

Volume Ratio:0.38

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.209

ROE:--

ROA:-44.38%

PB:-0.74

PE(LYR):-10.84

PS:24.00

Loading ...

Overview Company News Filings

CLOUDBREAK-B (02592): CBT-199 IND Application Effective, Clinical Trial Cleared for Safe Progression

Cloudbreak Pharma Inc. (Stock Code: 2592) Announces US FDA IND Approval for CBT-199

Bulletin Express

Cloudbreak Pharma Receives FDA Clearance to Begin Phase 2 Trials for CBT-199

BRIEF-Cloudbreak Pharma Inc Says Withdrawal Of Arbitration Proceedings On 28 Jan

Cloudbreak Pharma Inc. (2592) Announces Update on Settlement and Withdrawal of Arbitration Proceedings

Bulletin Express

Cloudbreak Pharma Arbitration Proceedings Withdrawn

Cloudbreak Pharma Inc - Withdrawal of Arbitration Proceedings on 28 Jan

THOMSON REUTERS

Cloudbreak Pharma Advances CBT-004 to Phase 3 Trials for Pinguecula Treatment

Cloudbreak Pharma Inc - No Treatment-Related Adverse Events Observed for Cbt-004

THOMSON REUTERS

Cloudbreak Pharma Inc - Phase 3 Data for Cbt-001 Anticipated in Q4 2026

THOMSON REUTERS

Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment With FDA on Phase 3 Path Forward for Cbt-004

THOMSON REUTERS

Cloudbreak Pharma Inc - to Complete Toxicity Studies in 2026 and Initiate Phase 3 in 2027

THOMSON REUTERS

Cloudbreak Pharma Grants 3 Million RSUs Tied to $100 Million Business Development Milestone

CLOUDBREAK-B Grants 8 Million Restricted Share Units Under Post-IPO Equity Incentive Plan

Cloudbreak Pharma Grants 8 Million Restricted Share Units Under Post-IPO Incentive Scheme

CLOUDBREAK-B (02592) Has Fully Paid the Settlement Amount to Cedar Wealth According to the Terms and Conditions of the Settlement Agreement

Cloudbreak Pharma Settles Legal Proceedings with Cedar Wealth

Cloudbreak Pharma Inc - Settlement of Legal Proceedings

THOMSON REUTERS

CLOUDBREAK-B (02592): Court Orders Judicial Preservation of CLOUDBREAK Guangzhou's Bank Account at ICBC Until November 30

BRIEF-Cloudbreak Pharma Inc Says Unit Receives Court Notice Dated 24 December

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02592/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02592","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"CLOUDBREAK-B","latestPrice":2.26,"timestamp":1771214886005,"preClose":2.25,"halted":0,"volume":95000,"delay":0,"changeRate":0.00444444444444435,"floatShares":850000000,"shares":850000000,"eps":-0.208525,"marketStatus":"Closed The third day of Lunar New Year","change":0.01,"latestTime":"02-16 12:08:06","open":2.25,"high":2.28,"low":2.24,"amount":214825,"amplitude":0.017778,"askPrice":2.29,"askSize":1000,"bidPrice":2.23,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":-0.386,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771551000000},"marketStatusCode":7,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":2.25,"openAndCloseTimeList":[[1771205400000,1771214400000]],"volumeRatio":0.38215395873906355,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","floatShares":850000000,"roa":"-44.38%","roe":"--","lyrEps":-0.208525,"volumeRatio":0.38215395873906355,"shares":850000000,"dividePrice":0,"high":2.28,"amplitude":0.017778,"preClose":2.25,"low":2.24,"week52Low":2.11,"pbRate":"-0.74","psRate":"24.00","week52High":9.74,"institutionHeld":0,"latestPrice":2.26,"committee":0.428571,"eps":-0.208525,"divideRate":0,"volume":95000,"delay":0,"ttmEps":-0.386,"open":2.25,"prevYearClose":5.2,"prevWeekClose":2.25,"prevMonthClose":2.45,"prevQuarterClose":5.2,"fiveDayClose":2.28,"twentyDayClose":3.14,"sixtyDayClose":4.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02592\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02592\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02592\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02592\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02592","date":"2026-02-16","current":-5.854922,"percent":0.826923,"low":-24.505522,"twenty":-12.775919,"median":-7.943265,"eighty":-5.973213,"high":-5.348116,"avg":-9.84563,"sd":4.561705,"marketCap":1895897895},"quantilePoints":[{"date":"2025-07-04","current":-6.317277,"twenty":-6.610502,"median":-6.500542,"eighty":-6.390583,"marketCap":4915912241},{"date":"2025-07-11","current":-6.166376,"twenty":-6.470405,"median":-6.317277,"eighty":-6.263403,"marketCap":4798467239},{"date":"2025-07-18","current":-6.350904,"twenty":-6.498689,"median":-6.350281,"eighty":-6.263403,"marketCap":4941079027},{"date":"2025-07-25","current":-6.080141,"twenty":-6.48004,"median":-6.306537,"eighty":-6.134066,"marketCap":4731355809},{"date":"2025-08-01","current":-5.497985,"twenty":-6.418895,"median":-6.177156,"eighty":-6.011186,"marketCap":4278353657},{"date":"2025-08-08","current":-5.49809,"twenty":-6.350655,"median":-6.13405,"eighty":-5.65539,"marketCap":4278353657},{"date":"2025-08-15","current":-5.725306,"twenty":-6.343182,"median":-6.058573,"eighty":-5.554248,"marketCap":4446132232},{"date":"2025-08-22","current":-5.53457,"twenty":-6.315129,"median":-6.004685,"eighty":-5.554248,"marketCap":4286742586},{"date":"2025-08-29","current":-5.503941,"twenty":-6.295753,"median":-5.870846,"eighty":-5.538055,"marketCap":4253186871},{"date":"2025-09-05","current":-5.413205,"twenty":-6.239682,"median":-5.742284,"eighty":-5.49926,"marketCap":4186075441},{"date":"2025-09-12","current":-12.640894,"twenty":-6.350655,"median":-5.870846,"eighty":-5.508123,"marketCap":4118964011},{"date":"2025-09-19","current":-12.711577,"twenty":-6.612702,"median":-6.004685,"eighty":-5.525012,"marketCap":4135741868},{"date":"2025-09-26","current":-11.804503,"twenty":-12.358821,"median":-6.058573,"eighty":-5.527436,"marketCap":3842129362},{"date":"2025-10-03","current":-6.439136,"twenty":-12.191113,"median":-6.134046,"eighty":-5.53457,"marketCap":2096453591},{"date":"2025-10-10","current":-5.988337,"twenty":-11.881825,"median":-6.134089,"eighty":-5.548508,"marketCap":1949083838},{"date":"2025-10-17","current":-12.3346,"twenty":-12.21981,"median":-6.187936,"eighty":-5.561014,"marketCap":4009907937},{"date":"2025-10-24","current":-11.844495,"twenty":-12.25273,"median":-6.279578,"eighty":-5.580054,"marketCap":3850518291},{"date":"2025-10-31","current":-12.15705,"twenty":-12.335851,"median":-6.333467,"eighty":-5.585568,"marketCap":3951185436},{"date":"2025-11-07","current":-11.838569,"twenty":-12.273198,"median":-6.424535,"eighty":-5.601607,"marketCap":3850518291},{"date":"2025-11-14","current":-11.510378,"twenty":-12.207573,"median":-6.465107,"eighty":-5.621104,"marketCap":3741462218},{"date":"2025-11-21","current":-12.23865,"twenty":-12.234818,"median":-6.500592,"eighty":-5.630174,"marketCap":3984741151},{"date":"2025-11-28","current":-21.343443,"twenty":-12.412307,"median":-6.613869,"eighty":-5.677994,"marketCap":6946032996},{"date":"2025-12-05","current":-20.614529,"twenty":-12.626633,"median":-6.790202,"eighty":-5.718633,"marketCap":6711142992},{"date":"2025-12-12","current":-17.961539,"twenty":-12.716498,"median":-11.142834,"eighty":-5.735493,"marketCap":5847083331},{"date":"2025-12-19","current":-14.819321,"twenty":-12.837409,"median":-11.27102,"eighty":-5.75741,"marketCap":4823634025},{"date":"2025-12-24","current":-14.055026,"twenty":-12.984934,"median":-11.600706,"eighty":-5.767869,"marketCap":4571966163},{"date":"2026-01-02","current":-11.620216,"twenty":-12.995771,"median":-11.729724,"eighty":-5.769371,"marketCap":3783406861},{"date":"2026-01-09","current":-7.540769,"twenty":-12.961935,"median":-11.510378,"eighty":-5.972321,"marketCap":2457956120},{"date":"2026-01-16","current":-8.049692,"twenty":-12.941587,"median":-11.169175,"eighty":-5.988337,"marketCap":2625734695},{"date":"2026-01-23","current":-6.609576,"twenty":-12.863288,"median":-10.620058,"eighty":-5.996682,"marketCap":2155954686},{"date":"2026-01-30","current":-6.294491,"twenty":-12.820156,"median":-9.452561,"eighty":-6.004685,"marketCap":2055287541},{"date":"2026-02-06","current":-5.800172,"twenty":-12.797534,"median":-8.075865,"eighty":-6.004685,"marketCap":1895897895},{"date":"2026-02-13","current":-5.772062,"twenty":-12.788929,"median":-7.957902,"eighty":-5.976779,"marketCap":1887508966},{"date":"2026-02-16","current":-5.798666,"twenty":-12.775919,"median":-7.943265,"eighty":-5.973213,"marketCap":1895897895}],"updateTime":1771498479400},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02592\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1179840902","title":"CLOUDBREAK-B (02592): CBT-199 IND Application Effective, Clinical Trial Cleared for Safe Progression","url":"https://stock-news.laohu8.com/highlight/detail?id=1179840902","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179840902?lang=en_us&edition=fundamental","pubTime":"2026-02-16 12:48","pubTimestamp":1771217311,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that its wholly-owned subsidiary, ADS Therapeutics LLC (ADS USA), incorporated in Delaware, United States, has completed the review period for the Investigational New...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","CBT","BK1161","BK4090"],"gpt_icon":0},{"id":"1146293952","title":"Cloudbreak Pharma Inc. (Stock Code: 2592) Announces US FDA IND Approval for CBT-199","url":"https://stock-news.laohu8.com/highlight/detail?id=1146293952","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146293952?lang=en_us&edition=fundamental","pubTime":"2026-02-16 12:41","pubTimestamp":1771216899,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. (Stock Code: 2592) released a voluntary announcement stating that the investigational new drug (IND) application for CBT-199, filed on 12 December 2025 with the United States...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"gpt_icon":0},{"id":"2611080211","title":"Cloudbreak Pharma Receives FDA Clearance to Begin Phase 2 Trials for CBT-199","url":"https://stock-news.laohu8.com/highlight/detail?id=2611080211","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611080211?lang=en_us&edition=fundamental","pubTime":"2026-02-16 12:34","pubTimestamp":1771216490,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. announced that its wholly-owned subsidiary, ADS Therapeutics LLC, has received confirmation from the U.S. Food and Drug Administration  that its Investigational New Drug  application for CBT-199, a potential ophthalmic treatment for presbyopia, has become effective. The FDA did not issue any clinical hold, allowing the clinical trial to proceed. This regulatory development authorizes Cloudbreak Pharma Inc. to initiate Phase 2 clinical trials of CBT-199 in the United States. The company stated that it will continue to monitor the evaluation process and provide updates as appropriate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260216:nNDL6X8gVL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2607033353","title":"BRIEF-Cloudbreak Pharma Inc Says Withdrawal Of Arbitration Proceedings On 28 Jan","url":"https://stock-news.laohu8.com/highlight/detail?id=2607033353","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607033353?lang=en_us&edition=fundamental","pubTime":"2026-01-29 22:06","pubTimestamp":1769695563,"startTime":"0","endTime":"0","summary":"BRIEF-Cloudbreak Pharma Inc Says Withdrawal Of Arbitration Proceedings On 28 JanJan 29 (Reuters) - Cloudbreak Pharma Inc 2592.HK:WITHDRAWAL OF ARBITRATION PROCEEDINGS ON 28 JANFurther company coverage: 2592.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YU0LE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0},{"id":"1111885053","title":"Cloudbreak Pharma Inc. (2592) Announces Update on Settlement and Withdrawal of Arbitration Proceedings","url":"https://stock-news.laohu8.com/highlight/detail?id=1111885053","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111885053?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:05","pubTimestamp":1769691918,"startTime":"0","endTime":"0","summary":"Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited disclaim responsibility for the contents of the announcement of Cloudbreak Pharma Inc. (the “Company”), make no...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"gpt_icon":0},{"id":"2607608422","title":"Cloudbreak Pharma Arbitration Proceedings Withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2607608422","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607608422?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:24","pubTimestamp":1769689499,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. has provided an update regarding its recent litigation. The company announced that arbitration proceedings involving Cloudbreak Guangzhou and Cedar Wealth have been withdrawn following an application by Cedar Wealth. The Arbitration Commission approved this withdrawal, and Cedar Wealth will bear the arbitration fees. Cloudbreak Pharma Inc. stated it will continue to inform shareholders and potential investors of any further developments related to the settlement of the proceedings. Shareholders are advised to exercise caution when dealing in the company’s securities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the I","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDLc8LTvk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2607084247","title":"Cloudbreak Pharma Inc - Withdrawal of Arbitration Proceedings on 28 Jan","url":"https://stock-news.laohu8.com/highlight/detail?id=2607084247","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607084247?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:24","pubTimestamp":1769689479,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YU0LE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2606731986","title":"Cloudbreak Pharma Advances CBT-004 to Phase 3 Trials for Pinguecula Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2606731986","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606731986?lang=en_us&edition=fundamental","pubTime":"2026-01-28 01:34","pubTimestamp":1769535269,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. has announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration  regarding the development of CBT-004 for the treatment of pinguecula. The company has reached alignment with the FDA on the Phase 3 study design, which will include primary efficacy endpoints previously achieved in the Phase 2 trial. Cloudbreak plans to assess efficacy at three months and safety at twelve months in the upcoming Phase 3 program, which is expected to begin in the first quarter of 2027 following the completion of remaining toxicity studies in 2026. Additionally, Phase 3 data from CBT-001, a potential treatment for pterygium, is anticipated in the fourth quarter of 2026. Results from the Phase 3 studies have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDLbjFcRy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2210150020.SGD","02592","LU2095319765.USD","SG9999014021.USD","NDAQ","IE00B64PRP62.GBP","BK1161","LU2210149790.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2606844087","title":"Cloudbreak Pharma Inc - No Treatment-Related Adverse Events Observed for Cbt-004","url":"https://stock-news.laohu8.com/highlight/detail?id=2606844087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606844087?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA6BRTWL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2606841037","title":"Cloudbreak Pharma Inc - Phase 3 Data for Cbt-001 Anticipated in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606841037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606841037?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA6BRTWL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2606784984","title":"Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment With FDA on Phase 3 Path Forward for Cbt-004","url":"https://stock-news.laohu8.com/highlight/detail?id=2606784984","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606784984?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518804,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA6BRTWL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2606476784","title":"Cloudbreak Pharma Inc - to Complete Toxicity Studies in 2026 and Initiate Phase 3 in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2606476784","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606476784?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518804,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA6BRTWL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2605459436","title":"Cloudbreak Pharma Grants 3 Million RSUs Tied to $100 Million Business Development Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2605459436","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605459436?lang=en_us&edition=fundamental","pubTime":"2026-01-22 12:11","pubTimestamp":1769055106,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. has announced a supplemental grant of 3,000,000 Restricted Share Units  under its Post-IPO Share Incentive Scheme. The RSUs have a performance target tied to the Group signing business development agreements totaling US$100 million in combined upfront payments and potential milestone payments. The performance target can be met in whole or in part based on the value of signed agreements, with RSUs vesting pro-rata as milestones are reached. The grant involves Whitcup Life Sciences LLC, a service provider wholly-owned by Dr. Scott Whitcup, which offers research, development, and business development services to the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDLc2xfT3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"1127281663","title":"CLOUDBREAK-B Grants 8 Million Restricted Share Units Under Post-IPO Equity Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1127281663","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127281663?lang=en_us&edition=fundamental","pubTime":"2026-01-18 17:32","pubTimestamp":1768728720,"startTime":"0","endTime":"0","summary":"On January 16, 2026, the company announced that it has granted a total of 8 million restricted share units under its post-initial public offering equity incentive plan. These units, equivalent to 8...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2603969685","title":"Cloudbreak Pharma Grants 8 Million Restricted Share Units Under Post-IPO Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2603969685","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603969685?lang=en_us&edition=fundamental","pubTime":"2026-01-16 17:09","pubTimestamp":1768554563,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. has announced the grant of restricted share units  under its Post-IPO Equity Incentive Scheme. The company will grant 5,000,000 RSUs to one employee and 3,000,000 RSUs to one service provider, with the grant date set for 16 January 2026. Any unvested RSUs will be forfeited if the grantee leaves the company or is found, in the company’s view, to have materially breached employment terms or failed to meet required performance standards. No financial assistance was provided to grantees to facilitate the purchase of shares under this scheme.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service oper","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL1SWYxM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"1181823282","title":"CLOUDBREAK-B (02592) Has Fully Paid the Settlement Amount to Cedar Wealth According to the Terms and Conditions of the Settlement Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=1181823282","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181823282?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:36","pubTimestamp":1768480586,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced details regarding, among other matters, legal proceedings initiated by Cedar Wealth against the company's indirectly wholly-owned subsidiary, CLOUDBREAK Guangzhou. On...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2603024986","title":"Cloudbreak Pharma Settles Legal Proceedings with Cedar Wealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2603024986","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603024986?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:19","pubTimestamp":1768479573,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. has announced the settlement of legal proceedings related to a dispute with Cedar Wealth. The case involved an asset preservation order on Cloudbreak Guangzhou, a wholly owned subsidiary, which froze approximately RMB2.55 million in its bank account following arbitration initiated by Cedar Wealth. The company stated that the settlement is not expected to have a material adverse impact on its overall business, operations, or cash flow. Business and operations remain normal, and shareholders are advised to exercise caution when dealing in the company’s shares. Further updates will be provided as appropriate in accordance with regulatory requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDLbhr5LH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2603608602","title":"Cloudbreak Pharma Inc -  Settlement of Legal Proceedings","url":"https://stock-news.laohu8.com/highlight/detail?id=2603608602","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603608602?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:18","pubTimestamp":1768479532,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YG0C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02592","BK1161"],"gpt_icon":0},{"id":"1157588045","title":"CLOUDBREAK-B (02592): Court Orders Judicial Preservation of CLOUDBREAK Guangzhou's Bank Account at ICBC Until November 30","url":"https://stock-news.laohu8.com/highlight/detail?id=1157588045","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157588045?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:58","pubTimestamp":1767797915,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that on January 6, 2026, CLOUDBREAK Biopharmaceutical Technology (Guangzhou) Co., Ltd., an indirect wholly-owned subsidiary, received a notice issued by the Guangzhou...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","161121","02592"],"gpt_icon":0},{"id":"2601046658","title":"BRIEF-Cloudbreak Pharma Inc Says Unit Receives Court Notice Dated 24 December","url":"https://stock-news.laohu8.com/highlight/detail?id=2601046658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601046658?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:57","pubTimestamp":1767797842,"startTime":"0","endTime":"0","summary":"BRIEF-Cloudbreak Pharma Inc Says Unit Receives Court Notice Dated 24 DecemberJan 7  - Cloudbreak Pharma Inc 2592.HK:UNIT RECEIVES COURT NOTICE DATED 24 DECEMBERCOURT ORDERS PRESERVATION OF CLOUDBREAK GUANGZHOU'S RMB2.55 MILLION ACCOUNT TILL NOV 30, 2026Further company coverage: 2592.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y816E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":70,"code":"91000000","status":"200"}]}}